TriSalus Life Sciences, Inc. (Nasdaq: TLSI), an oncology company integrating novel delivery technology with standard-of-care therapies and an investigational i
On June 09, 2026, Warrior Met Coal Inc (HCC) shares fell 4.3% to a current price of $94.67, continuing a downward trend noted over the past week with a decline
[url="]Exelixis, Inc.[/url] (Nasdaq: EXEL) today announced results from a subgroup analysis of the phase 3 CABINET pivotal trial, which showed that CABOMETYXÂ
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced that calderasib (MK-1084), an investigational oral specific KRAS G12C inhibi
AstraZeneca's IMFINZIÂ (durvalumab) in combination with Bacillus Calmette-GuÃrin (BCG) induction and maintenance therapy has been approved in the US for the
Warrior Met Coal (HCC) came out with quarterly earnings of $1.37 per share, beating the Zacks Consensus Estimate of $1.21 per share. This compares to a loss of $0.16 per share a year ago.
BROOKWOOD, Ala.--(BUSINESS WIRE)--Warrior Met Coal, Inc. (NYSE: HCC) (“Warrior” or the “Company”) today announced results for the first quarter of 2026. Warrior is the leading dedicated U.S.-based producer and exporter of high-quality steelmaking coal for the global steel industry. Warrior reported net income for the first quarter of 2026 of $72.3 million, or $1.37 per diluted share, an increase from a net loss of $8.2 million, or $0.16 per diluted share, in the first quarter of 2025. Adjusted.
BROOKWOOD, Ala.--(BUSINESS WIRE)--Warrior Met Coal, Inc. (NYSE:HCC) (“Warrior” or the “Company”) today announced that its board of directors has approved a regular quarterly cash dividend of $0.08 per share to be paid on May 7, 2026, to stockholders of record as of the close of business on May 1, 2026. About Warrior Warrior is a U.S.-based, environmentally, and socially minded supplier to the global steel industry. It is dedicated entirely to mining non-thermal metallurgical (met) coal used as.